Items Tagged ‘Tykerb’

May 11, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer


The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb

March 24, 2015

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer


In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than Tykerb® (lapatinib) plus a taxane, according to final clinical trial results reported in the Journal of Clinical Oncology. The HER2 […]

View full entry

Tags: Breast Cancer, HER2, herceptin, lapatinib, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, trastuzumab, Tykerb

June 10, 2014

Tykerb and Herceptin Combination Therapy Fails to Improve Outcomes for Early Stage HER2 Breast Cancer


Dr. Martine Piccart-Gebhart presented results at the 2014 annual meeting of the American Society of Clinical Oncology showing that a combination treatment of Tykerb® (lapatinib) and Herceptin® (trastuzumab) offered no benefit in outcomes for early stage HER2-positive breast cancer patients. Twenty to thirty percent of breast cancers overexpress (make too much of) a protein known […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, HER2, herceptin, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Tykerb